Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 15, 2008

Primary Completion Date

May 1, 2009

Study Completion Date

May 15, 2009

Conditions
Immune Thrombocytopenic Purpura
Interventions
DRUG

LGD-4665

LGD-4665 Thrombopoietin mimetic

DRUG

Placebo

Placebo

Trial Locations (15)

10021

Joan and Sanford I. Weill Medical College, Cornell University, New York

10029

Mount Sinai School of Medicine, New York

30341

Georgia Cancer Specialists, Atlanta

32207

Baptist Cancer Institute, Jacksonville

32806

Cancer Center of Florida, Orlando

44195

Cleveland Clinic Foundation, Univ. of Ohio, Cleveland

48201

Karmanos Cancer Center, Wertz Clinical Cancer Center 4HWCRC, Detroit

48202

Henry Ford Health System, Detroit

63110

Washington University School of Medicine - St Louis, MO, St Louis

78229

Hematology Oncology Associates of South Texas, San Antonio

87109

New Mexico Oncology Hematology Consultants, Albuquerque

92103-8409

University of California San Diego Medical Center, San Diego

94143-1270

University of California, San Francisco, San Francisco

06040

Davis, Posteraro and Wasser, MD's LLP, Manchester

44106-7284

Case Western Reserve University School of Medicine, Cleveland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY